# David Berry, MD PhD > David Berry is Managing Partner and Co-Founder of Averin Capital, an early-stage venture capital firm focused on AI and breakthrough technologies transforming human health, including areas such as quantum computing and robotics. A physician, scientist, entrepreneur, and investor, he brings scientific and medical expertise together with experience building and leading companies. ## About - [Home page](https://davidaberry.com/): Managing Partner & Co-Founder, Averin Capital - [Full profile (llms-full.txt)](https://davidaberry.com/llms-full.txt): Complete bio, experience, education, board roles, and writing - [Averin Capital](https://averincapital.com): Venture capital firm co-founded by David Berry ## Writing - [Accelerating the Speed of Discovery](https://www.averincapital.com/insights/accelerating-the-speed-of-discovery): What does it take to accelerate drug discovery without losing the scientific judgment that makes better medicines possible? I sit down with Andy Plump,… - [The Case for Drug Abundance](https://www.averincapital.com/insights/the-case-for-drug-abundance): What if the cost of developing a medicine no longer determined which diseases get treated? The Case for Drug Abundance explores how advances in AI, human… - [Betting on Breakthrough Biology](https://www.averincapital.com/insights/betting-on-breakthrough-biology): How do you spot the next big idea in biotech before everyone else does? I sit down with Christian Schubert, Vice President and Global Head of AbbVie… - [Before Disease Decides](https://www.averincapital.com/insights/before-disease-decides): What if diagnostics could tell us not just what disease a patient has, but what is beginning to happen next? I sit down with QIAGEN CEO Thierry Bernard… - [Welcoming Dr. Mikael Dolsten to the Averin Advisory Board](https://www.averincapital.com/insights/welcoming-dr-mikael-dolsten-to-the-averin-advisory-board): We are excited to announce that Dr. Mikael Dolsten has joined Averin Capital as an advisor. A physician-scientist and biotechnology leader with more than… - [The Surgeon Is Still the System](https://www.averincapital.com/insights/the-surgeon-is-still-the-system): The next era of surgery will not be defined by robots alone, but by integrated systems of AI, visualization, and precision tools that expand what surgeons… - [Diagnostics Isn’t Broken. Our Model for Evaluating It Is](https://www.averincapital.com/insights/diagnostics-isnt-broken-our-model-for-evaluating-it-is): Investor sentiment has turned against diagnostics, but for the wrong reasons. Recent failures have hardened a lazy narrative that the category is… - [Regulation, AI, and Geopolitics: Insights from Our Latest Fireside Chat](https://www.averincapital.com/insights/regulation-ai-and-geopolitics-insights-from-our-latest-fireside-chat): In a candid conversation with Peter Hutt, David Shulkin, and Daniel Troy, we cut through headline noise to find a clear pattern - despite few formal… - [The FDA’s Shifting Regulatory Landscape](https://www.averincapital.com/insights/the-fdas-shifting-regulatory-landscape): The FDA has shifted from a distant gatekeeper to an active force shaping how health-tech companies build, sell, and exit. Regulatory cycles are… - [AI’s Leap in Healthcare and Biotech: Insights from Our Latest Fireside Chat](https://www.averincapital.com/insights/ais-leap-in-healthcare-and-biotech-insights-from-our-latest-fireside-chat): Averin’s David Berry hosts a conversation with leaders from XYME, AWS, and Bioptic to explore how AI is transforming drug discovery, data infrastructure,… - [Alzheimer’s Disease — Why We May Be Entering a New Era of Drug Development](https://www.averincapital.com/insights/alzheimers-disease-why-we-may-be-entering-a-new-era-of-drug-development): Advancements in trial design, disease hypothesis, therapeutic pathways and diagnostics give us hope that in the next 10-15 years, the life sciences… - [How Startups Can Help Shift America to a Prevention First Health System](https://www.averincapital.com/insights/how-startups-can-help-with-the-transformation-to-preventation-care): The systemic disposition towards a treatment-first approach - focusing on managing illnesses - rather than a preventative-first approach is at the heart… - [Continuous Glucose Monitors and the Future of Real-Time Biosensing](https://www.averincapital.com/insights/continuous-glucose-monitors-and-the-future-of-real-time-biosensing): CGMs are among the most important personal medical devices. While they are prevalent today, important changes in their design, accuracy, and the scope of… - [Liquid Biopsies: Revolutionizing Non-Invasive Cancer Diagnostics](https://www.averincapital.com/insights/liquid-biopsies-revolutionizing-non-invasive-cancer-diagnosticsnbspnbsp): Groundbreaking improvements in the technologies for liquid biopsies have marked a tipping point in accuracy and reliability, resulting in a significant… - [How Digital Diagnostics and Artificial Intelligence Can Transform Healthcare](https://www.averincapital.com/insights/digital-diagnostics-artificial-intelligence): AI has the potential to change the role of the doctor, and diagnostics is one of the first areas where we’re seeing a dramatic change. We discuss how… ## Links - [LinkedIn](https://www.linkedin.com/in/davidberrymdphd)